Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Pharmaceuticals
Includes predecessor: J.B. Chemicals & Pharmaceuticals Ltd. (till 8 Jul 2026)
Snapshot
Unlock Torrent Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Torrent Pharmaceuticals Limited is a prominent Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations. The company operates across diverse therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and diabetology, while also providing contract manufacturing services.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical products across domestic and international markets. It further leverages licensing collaborations for specialized portfolios and provides contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by the expansion of its diverse therapeutic portfolio and strategic licensing agreements for specialized treatments. The company continues to focus on strengthening its presence in key international markets including the United States, Germany, and Brazil.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may compress profit margins.
- Currency Volatility. As a significant exporter to the US, Germany, and Brazil, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
- R&D Execution. The ability to successfully develop and commercialise new generic formulations in a timely manner is critical to maintaining market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Torrent Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹17,400 Cr
TTM · consolidated
NET PROFIT
₹2,099 Cr
TTM · consolidated
EPS
₹59.20
TTM · consolidated
RETURN ON EQUITY
15.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
77.6×
Q2 FY27 · consolidated
EV/EBITDA
32.8x
Q2 FY27 · consolidated
EBITDA MARGIN
32.9%
TTM · consolidated
NET PROFIT MARGIN
10.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.8x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.75L Cr | 77.6× | 32.81 | 42.1% | 32.9% | 15.7% | 15.5% | +29.1% |
Laurus Labs Ltd.LAURUSLABS | ₹1.27L Cr | 94.6× | 53.43 | 23.0% | 30.9% | 24.5% | 27.9% | +146.2% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.24L Cr | 27.6× | 15.34 | 21.1% | 30.7% | 18.0% | 20.1% | +27.3% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 38.7× | 20.10 | -0.7% | 19.6% | 8.4% | 11.1% | -7.6% |
Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1.12L Cr | 39.9× | 19.05 | -3.5% | 18.5% | 7.4% | 9.8% | +12.1% |
Mankind Pharma Ltd.MANKIND | ₹1.02L Cr | 45.7× | 24.25 | 13.9% | 28.6% | 13.8% | 15.0% | +4.1% |
As of Q2 FY27
Financials
Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Pharmaceuticals
Includes predecessor: J.B. Chemicals & Pharmaceuticals Ltd. (till 8 Jul 2026)
Snapshot
Unlock Torrent Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Torrent Pharmaceuticals Limited is a prominent Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations. The company operates across diverse therapeutic areas including cardiovascular, central nervous system, gastrointestinal, and diabetology, while also providing contract manufacturing services.
Business Model
The company generates revenue through the sale of branded and generic pharmaceutical products across domestic and international markets. It further leverages licensing collaborations for specialized portfolios and provides contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by the expansion of its diverse therapeutic portfolio and strategic licensing agreements for specialized treatments. The company continues to focus on strengthening its presence in key international markets including the United States, Germany, and Brazil.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to import bans or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector and government-mandated price controls in India may compress profit margins.
- Currency Volatility. As a significant exporter to the US, Germany, and Brazil, the company is exposed to fluctuations in foreign exchange rates that can impact reported earnings.
- R&D Execution. The ability to successfully develop and commercialise new generic formulations in a timely manner is critical to maintaining market share against global peers.
Start your research today
Unlock AI insights, financials, peers and live data on Torrent Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹17,400 Cr
TTM · consolidated
NET PROFIT
₹2,099 Cr
TTM · consolidated
EPS
₹59.20
TTM · consolidated
RETURN ON EQUITY
15.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.5%
TTM · consolidated
P/E
77.6x
Q2 FY27 · consolidated
EV/EBITDA
32.8x
Q2 FY27 · consolidated
EBITDA MARGIN
32.9%
TTM · consolidated
NET PROFIT MARGIN
10.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.8x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27